Claus R. Bartram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claus R. Bartram has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alfons Meindl
Department of Gynaecology and Obstetrics, Klinikum rechts der Isar at the Technical University, Munich, Germany
2 shared publications - Barbara Burwinkel
Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center, DKFZ, Heidelberg, Germany
2 shared publications - Barbara Wappenschmidt
Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Germany
2 shared publications - Bernd Frank
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
2 shared publications - Christian Sutter
Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
2 shared publications - Kari Hemminki
Biomedical Center, Faculty of Medicine Charles University Pilsen Pilsen Czech Republic
2 shared publications
Latest Publications
- 5 October 2012
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 109 (40) , 652-8
Acute Lymphoblastic Leukemia in Children
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children (aged 1?18 years), accounting for almost 30% of all cancers in this age group. In Germany, every year four in every 100 000 children aged up to 15 develop ALL (Box). Almost...
- 5 October 2012
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 109 (40) , 652-8
Acute Lymphoblastic Leukemia in Children
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children (aged 1?18 years), accounting for almost 30% of all cancers in this age group. In Germany, every year four in every 100 000 children aged up to 15 develop ALL (Box). Almost...
- Open Access
- 15 May 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 83
BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study
Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC). We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571 German BC families and 712 control individuals. No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed. We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.
- 15 May 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 83
Open AccessBRIP1 (BACH1) variants and familial breast cancer risk: a case-control study
Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC). We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571 German BC families and 712 control individuals. No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed. We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.
- Open Access
- 17 November 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 268
Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study
The transcription factor 7-like 2 (TCF7L2) is a critical component of the Wnt/β-catenin pathway. Aberrant TCF7L2 expression modifies Wnt signaling and mediates oncogenic effects through the upregulation of c-MYC and cyclin D. Genetic alterations in TCF7L2 may therefore affect cancer risk. Recently, TCF7L2 variants, including the microsatellite marker DG10S478 and the nearly perfectly linked SNP rs12233372, were identified to associate with type 2 diabetes. We investigated the effect of the TCF7L2 rs12255372 variant on familial breast cancer (BC) risk by means of TaqMan allelic discrimination, analyzing BRCA1/2 mutation-negative index patients of 592 German BC families and 735 control individuals. The T allele of rs12255372 showed an association with borderline significance (OR = 1.19, 95% C.I. = 1.01-1.42, P = 0.04), and the Cochran-Armitage test for trend revealed an allele dose-dependent association of rs12255372 with BC risk (P trend = 0.04). Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.
- 17 November 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 268
Open AccessTranscription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study
The transcription factor 7-like 2 (TCF7L2) is a critical component of the Wnt/β-catenin pathway. Aberrant TCF7L2 expression modifies Wnt signaling and mediates oncogenic effects through the upregulation of c-MYC and cyclin D. Genetic alterations in TCF7L2 may therefore affect cancer risk. Recently, TCF7L2 variants, including the microsatellite marker DG10S478 and the nearly perfectly linked SNP rs12233372, were identified to associate with type 2 diabetes. We investigated the effect of the TCF7L2 rs12255372 variant on familial breast cancer (BC) risk by means of TaqMan allelic discrimination, analyzing BRCA1/2 mutation-negative index patients of 592 German BC families and 735 control individuals. The T allele of rs12255372 showed an association with borderline significance (OR = 1.19, 95% C.I. = 1.01-1.42, P = 0.04), and the Cochran-Armitage test for trend revealed an allele dose-dependent association of rs12255372 with BC risk (P trend = 0.04). Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.